Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey
Open Access
- 12 March 2013
- journal article
- Published by Springer Nature in Health Economics Review
- Vol. 3 (1) , 5
Abstract
This study aimed to apply the previously validated severity index for rheumatoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey and determine the effect of RA severity on health care costs and biologic use. This retrospective study used the Turkish national health insurance database MEDULA (June 1, 2009-December 31, 2011). Prevalent RA patients were required to be age 18 to 99, have two RA diagnoses at least 60 days apart and be continuously enrolled 1 year prior to (baseline period) and post (follow-up period) index date, which was the first RA claim during the identification period (June 1, 2010-December 31, 2010). SIFRA was calculated for the baseline period. Total health care costs and biologic use were examined for the follow-up period. The chi-square test was used to determine the association between SIFRA score terciles and outcomes. Generalized linear models were applied to determine health care costs while multivariate logistic regression determined the effect of SIFRA on outcome measures for biologic use. A total of 1,920 patients were identified. The mean SIFRA score was 14.21, and 7.05 (49.57%) of the mean composed of clinical and functional status variables, followed by 6.32 (44.47%) for medications, 0.48 (3.40%) for radiology and laboratory findings, and 0.32 (2.25%) for extra-articular manifestation. There was a significant variation in scores across cities. After controlling for age, gender, region, and comorbidity index, patients in the high SIFRA tercile were 5.16 times more likely to be prescribed biologics (p<0.001, confidence interval [CI]: 3.46-7.69), and incurred annual health care costs that were €2,091 higher (p<0.001, CI: €1,557 - €2,625) than those in the low SIFRA score tercile. RA severity varies throughout Turkey and is a significant determinant of health care costs and biologic therapy use. Therefore, future comparative effectiveness studies should include the severity measure in their analysis.Keywords
This publication has 30 references indexed in Scilit:
- Advances in the Medical Treatment of Rheumatoid ArthritisHand Clinics, 2011
- Societal cost of rheumatoid arthritis patients in the USCurrent Medical Research and Opinion, 2009
- Too Much Ado about Instrumental Variable Approach: Is the Cure Worse than the Disease?Value in Health, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Development and assessment of indicators of rheumatoid arthritis severity: Results of a Delphi panelArthritis Care & Research, 2005
- Determinants of direct costs in Dutch rheumatoid arthritis patientsAnnals of the Rheumatic Diseases, 2004
- Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: Effect of different methods of case classificationArthritis & Rheumatism, 2003
- The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritisArthritis & Rheumatism, 1986
- Evaluation: A Systematic ApproachEducational Researcher, 1980